Drugs / Pyrroloquinoline quinone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06431113 | Jan 2024 → Mar 2025 | glaucoma | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT06245083 Comparator | Dec 2024 → Aug 2025 | morbid obesity | University of Oklahoma | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyrroloquinoline quinone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06245083 ↗ |
| Known as | PQQ | “Pyrroloquinoline quinone (PQQ) is a diet-derived natural food supplement with anti-inflammatory properties that, in humans and mice, improves metabolism and exerts potent...” NCT06245083 ↗1“Pyrroloquinoline quinone (PQQ) disodium salt (Neuprozin Mito®)” NCT06431113 ↗ |
| Modality | Small molecule | — CHEMBL1235421 ↗ |
| Route | Oral | “Oral supplement taken daily” NCT06245083 ↗ |